<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372957</url>
  </required_header>
  <id_info>
    <org_study_id>DPB106653</org_study_id>
    <nct_id>NCT00372957</nct_id>
  </id_info>
  <brief_title>Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>PK/PD Study of GW823093 in Japanese Subjects With T2DM A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability
      of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2
      diabetes mellitus (T2DM) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic and Pharmacodynamic measurements during 7 days of dosing.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events Changes in clinical laboratory tests Vital signs 12-lead ECG during 7 days of dosing.</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Non-Insulin-Dependent Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW823093</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  T2DM diagnosed at least 3 months prior to Screening and fasting plasma glucose (FPG)
             level &lt;280mg/dL at the Screening visit.

          -  Concurrent T2DM therapy: Must be diet controlled - OR - not taking more than 2 oral
             anti-diabetic agents, and willing to withdraw from these treatments 2 weeks prior to
             the first dosing.

        Exclusion criteria:

          -  Must not have any other major illness other than diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 1, 2010</lastchanged_date>
  <firstreceived_date>September 5, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
